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Prevalence and Subtypes of 
Mild Cognitive Impairment in 
Parkinson’s Disease
Blake J. Lawrence1,2, Natalie Gasson1,2 & Andrea M. Loftus1,2
The current study examined the prevalence and subtypes of Mild Cognitive Impairment (MCI) in an 
Australian sample of people with Parkinson’s Disease (PD). Seventy participants with PD completed 
neuropsychological assessments of their cognitive performance, using MDS Task Force Level II 
diagnostic criteria for PD-MCI. A cut-off score of less than one standard deviation (SD) below normative 
data determined impaired performance on a neuropsychological test. Of 70 participants, 45 (64%) 
met Level II diagnostic criteria for PD-MCI. Among those with PD-MCI, 42 (93%) were identified as 
having multiple domain impairment (28 as amnestic multiple domain and 14 as nonamnestic multiple 
domain). Single domain impairment was less frequent (2 amnestic/1 nonamnestic). Significant 
differences were found between the PD-MCI and Normal Cognition groups, across all cognitive 
domains. Multiple domain cognitive impairment was more frequent than single domain impairment 
in an Australian sample of people with PD. However, PD-MCI is heterogeneous and current prevalence 
and subtyping statistics may be an artifact of variable application methods of the criteria (e.g., cut off 
scores and number of tests). Future longitudinal studies refining the criteria will assist with subtyping 
the progression of PD-MCI, while identifying individuals who may benefit from pharmacological and 
nonpharmacological interventions.
Parkinson’s disease (PD) is now understood as a multifaceted neurodegenerative disorder with heterogeneous 
motor and non-motor symptoms1. Approximately 30% of people with PD demonstrate cognitive impairment and 
up to 50% of those progress to PD-Dementia after more than 10 years of disease duration2,3. Cognitive impair-
ments in PD comprise four subtypes; amnestic single, amnestic multiple, nonamnestic single and nonamnestic 
multiple. The four subtypes reflect deficits across five cognitive domains, including: memory, attention/working 
memory, language, visuospatial, and executive functions4,5.
Several biological and epidemiological risk factors are associated with cognitive deficits in PD, with some 
studies reporting cognitive impairment is present even at time of diagnosis6,7. To standardize assessment, the 
Movement Disorder Society (MDS) Task Force developed new diagnostic criteria for PD-Mild Cognitive 
Impairment (PD-MCI)8. Preceding the criteria, most studies adopted the method proposed by Petersen et al.9 
which specifies a decline in memory. PD-MCI is, however, heterogeneous and many people demonstrate impair-
ments across the spectrum of cognitive domains10. Recent studies adopting the new MDS diagnostic criteria 
report variable results11,12. These studies also applied varying diagnostic cut off scores and weighting of tests per 
cognitive domain, which may influence the reported prevalence of cognitive impairment in PD.
The high prevalence and significant impact of cognitive impairment on quality of life for people with PD13, indi-
cate that any standardised criteria developed for international use needs to be validated and examined across mul-
tiple populations of PD. To date, no study has applied the MDS criteria for PD-MCI to an Australian sample. This 
study provided a novel application of the MDS Task Force PD-MCI Level II diagnostic criteria to an Australian 
sample of people with PD. This study also examined PD-MCI frequency differentials at varying diagnostic cut off 
scores to explore subtype classifications and advance our understanding of cognitive impairments in PD.
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Results
Seventy participants completed neuropsychological assessments, with 64.3% (N = 45) classified as ‘PD-MCI’ and 
the remaining participants classified as ‘PD-Normal Cognition (PD-NC)’ (N = 25). For demographic variables, 
there were no statistically significant group differences. There were significant differences between groups on all 
cognitive outcomes (excluding SOC). Table 1 provides demographic and neuropsychological test results for par-
ticipants in the PD-MCI and PD-NC groups.
Internal reliability varied between adequate (0.40 to 0.50) to excellent (> 0.90) and was computed for 10 
outcomes: UPDRS-II (α = 0.80) TISC (KR-20 = 0.47), MMSE (KR-20 = 0.54); PD-CRS (α = 0.84), LNS (KR-
20 = 0.92), Stroop (Colour-Word) Test (KR-20 = 0.96), BNT (KR-20 = 0.54), Similarities (α = 0.68), JLO (KR-
20 = 0.90) and HVLT (KR-20 = 0.78). Low internal reliability scores were identified for the TISC, MMSE, 
BNT and Similarities outcomes. However, due to the diversity of cognitive constructs, using cut off scores for 
Cronbach’s α may subtract from the scale’s primary purpose in the context of the research14. All outcomes were 
therefore reported in this study and the current authors suggest interpreting the outcomes with low reliability 
with caution.
PD-MCI subtypes according to MDS criteria. Among participants who met the MDS Task Force criteria 
for PD-MCI (N = 45), 93.4% demonstrated multiple domain impairment and only 6.6% showing single domain 
impairment (4.4% memory and 2.2% visuospatial; Fig. 1).
Cognitive deficits were heterogeneous among participants with multiple domain PD-MCI. In total, 62.2% 
(N = 28) of participants were classified as amnestic multiple domain with 11 different patterns of impairments 
identified (Table 2). Moreover, 31.2% (N = 14) of participants were classified as nonamnestic multiple domain and 
nine different patterns of impairments identified. When comparing individual cognitive domains for all PD-MCI 
(Fig. 2), executive function was impaired in 62.2% (N = 28) of participants, attention/working memory in 66.7% 
(N = 30), memory in 66.7% (N = 30), visuospatial in 31.2% (N = 14) and language in 44.4% (N = 20).
Domain Outcome
PD-MCI (N = 45) NC (N = 25) Diff. of means
M SD M SD t p
Gender (% male) 62.2% (N = 28) 64% (N = 16) — 0.88+
Age++ 68.53 9.92 64.12 7.10 − 1.96 0.05
Education++ 13.60 3.10 14.52 2.87 1.22 0.23
Premorbid IQ 106.97 8.01 106.81 21.71 -0.04 0.97
Disease Duration++ 5.81 4.58 5.90 4.99 0.08 0.94
LED 398.43 350.33 335.19 254.15 -0.79 0.43
UPDRS-II 1.08 0.62 0.89 0.54 − 1.30 0.20
Global TISC 22.42 2.95 24.48 2.47 2.96 0.004*
MMSE 25.56 2.95 27.84 1.62 3.57× 0.001*
PD-CRS 81.07 19.48 100.28 12.10 4.47× 0.001**
EF COWAT 32.24 15.01 45.80 12.36 3.85 0.001**
SOC 6.22 2.08 7.24 2.06 1.96 0.60
Atten.WM LNS (SS) 8.36 3.64 11.56 2.16 4.02 0.001**
LNS (RS) 16.09 5.88 20.52 2.43 3.59× 0.001*
Stroop Test 24.51 12.19 38.24 10.05 4.80 0.001**
Memory HVLT 21.60 6.82 28.80 5.48 4.53 0.001**
Paragraph Recall 4.56 2.31 7.08 1.79 4.71 0.001**
Language BNT 13.27 1.66 14.32 0.80 2.98× 0.001**
Similarities (SS) 8.76 1.88 10.84 1.52 4.74 0.001**
Similarities (RS) 21.09 3.97 26.40 2.75 5.93 0.001**
VS JLO 21.29 7.62 26.64 3.49 3.31× 0.001*
HVOT 22.11 3.96 25.24 2.10 4.32× 0.001**
Table 1. Comparison of demographic and neuropsychological test scores for PD-MCI and Normal 
Cognition groups. PD-MCI = Parkinson’s Disease-Mild Cognitive Impairment; NC = Normal Cognition; 
M = mean; SD = standard deviation; t = t-statistic; p = alpha level of significance; + = non-parametric Mann-
Whitney U test; ++ = years; × = equal variances not assumed; * = p < 0.05; ** = p < 0.001; Global = global 
cognition; EF = executive function; Atten./WM = Attention/working memory; VS = visuospatial; 
LED = levodopa equivalent dose; UPDRS-II = Unified Parkinson’s Disease Rating Scale-section 2 (activities 
of daily living); TISC = Telephone Interview for Cognitive Status; MMSE = Mini-Mental State Examination; 
PD-CRS = Parkinson’s Disease-Cognitive Rating Scale; COWAT = Controlled Oral Word Association 
Test; SOC = Stockings of Cambridge; LNS = Letter-Number Sequencing; SS = Scaled score; RS; Raw score; 
HVLT = Hopkin’s Verbal Learning Test; BNT = Boston Naming Test; JLO = Judgement of Line Orientation; 
HVOT = Hooper’s Visual Organisation Test.
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Post-hoc analyses. Following the high frequency of PD-MCI (64.3%) when using a 1 SD cut-off below nor-
mative data, post-hoc analyses were conducted to examine whether using a 2 SD cut off would result in frequency 
differentials (Table 3). The frequency of PD-MCI decreased from 64.3% to 28.6% (N = 20). Among participants 
with PD-MCI, however, the frequency of subtype classifications remained relatively stable. Overall, 90% (N = 18) 
of participants with PD-MCI demonstrated multiple domain impairment and only 10% showed single domain 
impairment (N = 1 for memory and N = 1 for attention/working memory). Amnestic multiple domain remained 
most frequent (N = 10, 50%) with five different patterns of impairments, followed by nonamnestic multiple 
domain (N = 8, 40%) with five different patterns of impairments. Both amnestic single and nonamnestic single 
domains showed the least frequency of impairment (N = 1, 5% individually). Following the 2 SD cut off, executive 
function was impaired in 75% (N = 15) of participants, attention/working memory in 45% (N = 9), memory in 
50% (N = 10), visuospatial in 45% (N = 9) and language in 10% (N = 2).
Discussion
This study was the first application of MDS Task Force criteria for PD-MCI in an Australian sample. Using the 
criteria at the 1 SD cut off score, 64.3% of participants were diagnosed as PD-MCI. Among those with PD-MCI, 
93.4% presented with multiple domain impairments (i.e., deficit test results in more than one cognitive domain), 
and 6.6% with single domain impairment. Attention/working memory, executive function, and memory impair-
ments were the most frequently impaired cognitive domains. Language and visuospatial domains demonstrated 
Figure 1. Distribution of PD-MCI subtypes using a one standard deviation cut off. 
PD-MCI Subtype Domains Impaired N (%)
Amnestic Multiple All domains 5 (11.1)
Memory + EF 5 (11.1)
Memory + Attention/WM 5 (11.1)
Memory + EF + Attention/WM 3 (6.7)
Memory + Attention/WM + Language 3 (6.7)
Memory + EF + Attention/WM + Language 2 (4.4)
Memory + EF + Attention/WM + Visuospatial 1 (2.2)
Memory + Attention/WM + Visuospatial 1 (2.2)
Memory + Language 1 (2.2)
Memory + EF + Language 1 (2.2)
Memory + Language + Visuospatial 1 (2.2)
Subtotal 28 (62.2)
Nonamnestic Multiple EF + Attention/WM 4 (8.8)
EF + Language 3 (6.7)
EF + Visuospatial 1 (2.2)
EF + Attention/WM + Language 1 (2.2)
EF + Attention/WM + Language + Visuospatial 1 (2.2)
EF + Attention/WM + Visuospatial 1 (2.2)
Attention/WM + Language 1 (2.2)
Attention/WM + Visuospatial 1 (2.2)
Attention/WM + Language + Visuospatial 1 (2.2)
Subtotal 14 (31.2)
Amnestic Single Memory 2 (4.4)
Nonamnestic Single Visuospatial 1 (2.2)
Total 45 (100)
Table 2.  Distribution of PD-MCI subtypes and domain impairments using a one standard deviation cut 
off score.  EF = Executive Function; Attention/WM = Attention/Working Memory.
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less impairment. These results support those of Cholerton et al.12 and Goldman et al.10 who found that 63–67% of 
their samples had PD-MCI and that 91.5–95% of those participants had multiple domain impairments. Marras 
et al.11 reported that 93% of their sample with PD-MCI had multiple domain impairment, despite an overall 
PD-MCI prevalence of only 33%. Recent application of the new criteria also revealed that attention/working 
memory, executive function and memory domains were most frequently impaired in PD-MCI10,12. These results, 
however, conflict with prevalence statistics preceding the new diagnostic criteria. Studies predating the criteria 
indicate a significantly lower prevalence (19% to 38%) of PD-MCI and some studies identified single domain 
impairment as more common than multiple domain impairment2,15,16.
Several reasons have been proposed for the varying frequency of PD-MCI across studies. Compared to pre-
vious methods, the new MDS criteria is less stringent when diagnosing multiple domain (i.e., impairment on 
one test per domain) compared to single domain (i.e., impairment on two tests in one domain) subtypes, which 
will invariably identify more people with multiple domain impairment10. Introducing a more conservative cri-
terion for the multiple domain subtype (e.g., impairment on two tests per domain) will likely reduce the biased 
Figure 2. Percentage of participants with cognitive impairment by domain when using a one standard 
deviation cut off. 
PD-MCI Subtype Domains Impaired N (%)
Amnestic Multiple Memory + EF 4 (20)
Memory + EF + Attention/WM + Visuospatial 3 (15)
Memory + EF + Attention/WM 1 (5)
Memory + Attention/WM 1 (5)
Memory + Language 1 (5)
Subtotal 10 (50)
Nonamnestic Multiple EF + Visuospatial 4 (20)
EF + Attention/WM 1 (5)
EF + Language 1 (5)
EF + Attention/WM + Visuospatial 1 (5)
Attention/WM + Visuospatial 1 (5)
Subtotal 8 (40)
Amnestic Single Memory 1 (5)
Nonamnestic Single Attention/WM 1 (5)
Total 20 (100)
Table 3. Distribution of PD-MCI subtypes and domain impairments using a two standard deviation cut off 
score.  EF = Executive Function; Attention/WM = Attention/Working Memory.
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frequency of multiple domain impairment. In addition, several verbal memory, visuospatial, and attention tests 
have demonstrated appropriate diagnostic specificity for PD-MCI17, and administering these tests in future 
research may provide a more accurate estimate of the multiple domain subtype.
In studies preceding the MDS Task Force criteria, variable use of SD cut offs increased the heterogeneity of the 
frequency of PD-MCI and this issue is yet to be resolved18. The new diagnostic criteria suggest 1 to 2 SD cut offs 
for establishing cognitive impairment with normative data8, but Liepelt-Scarfone et al.18 have shown that PD-MCI 
diagnoses vary between 56.4% (using < 1 SD) and 9.9% (using < 2 SDs). Having said this, a recent study identified 
2 SDs as the most sensitive and specific cut off for diagnosing PD-MCI using the new criteria10. Using a 2 SD cut 
off in the current study reduced the frequency of PD-MCI from 64.3% (using 1 SD) to 28.6%, but the frequency 
of subtype classifications remained relatively stable (i.e., multiple domain impairment remained more frequent 
than single domain). Language impairment, however, reduced from 44.4% (N = 20) using a 1 SD cut off to 10% 
(N = 2) using a 2 SD cut off. Compared to other cognitive domains, this result suggests that language impairment 
may be less frequent in PD-MCI. Impairment across all cognitive domains was prevalent among 11.1% (N = 5) of 
participants using a 1 SD cut off, but this reduced to nil participants using a 2 SD cut off. This finding supports the 
current characterisation of PD-MCI, with most individuals demonstrating impairment within multiple, but not 
all, cognitive domains (e.g., executive function and memory)12. Using a 1 SD cut off may, however, be too liberal 
and not sufficiently specific for identification of PD-MCI subtypes10. Overall, the reduction in the frequency of 
PD-MCI is similar to previous prevalence estimates that adopted more conservative 1.5 SD11 and 2 SD19 cut off 
scores. The MDS Task Force, however, suggest using a 1 SD cut off to detect impaired cognition in higher func-
tioning individuals, who may have noticed a decline in their cognitive functioning but do not meet the stricter 
criteria of 1.5 to 2 SDs8.
The inconsistent use of, and weighting of, cognitive tests per domain may also bias diagnosis and subtyping 
of PD-MCI. The MDS Task Force recommends two tests per cognitive domain to ensure consistency across 
studies and the reliable external validity of results8. Recent studies adopting the criteria have used between 3 and 
7 tests/subtests per domain, which is more than recommended10,12. Inclusion of more tests in any one domain 
increases the risk of a Type I error and may falsely inflate the prevalence of PD-MCI20. A recent study showed 
that when using MDS Task Force recommendations (10 or more neuropsychological tests), approximately 13% of 
people with PD and normal cognition will demonstrate impaired performance on two or more tests20. The recent 
increase in prevalence of PD-MCI may, therefore, be associated with the inclusion of more neuropsychological 
tests in the assessment of PD-MCI, which may lead to more false-positive diagnoses. As previously noted, a more 
conservative use of tests (e.g., impairment on two tests per domain) when diagnosing multiple domain PD-MCI 
and applying a more stringent cut off score (e.g., < 2 SDs below normative data) may reduce the risk of Type 1 
errors in research and clinical settings. While acknowledging these issues, further refinement of the PD-MCI 
criteria will determine the ideal classification method, appropriate cut off scores, and the optimal number and 
selection of tests for diagnosis.
Although recent studies have used varying cut off scores, subtype classifications in this study are consistent 
with recent findings21. Most participants were identified as multiple domain PD-MCI, which comprised 20 dif-
ferent combinations of impaired domains. Cholerton et al.12 also reported 19 combinations of impaired domains 
within their multiple domain subtype. Although this may be an artefact of the MDS diagnostic criteria (i.e., 1 SD 
cut off has shown low specificity10), this heterogeneous distribution across multiple domains is a hallmark feature 
of PD-MCI4. Research has identified diverse pathophysiological changes and characteristics that may underlie the 
heterogeneous presentation of PD-MCI3.
Most participants in this study demonstrated memory and executive function impairments, but there were 
considerable concomitant deficits across domains. The variability of PD-MCI has been associated with protein/
neurotransmitter abnormalities and genetic characteristics3. Catecholaminergic changes involving fronto-
striatal dopaminergic deficits are associated with executive function impairment, and deficiency of acetylcho-
line is associated with impaired posterior cortical function of memory, language and visuospatial abilities3,7,22. 
Alpha-synuclein infiltration (as Lewy based pathology) of the limbic system and neocortex has also been associ-
ated with amnestic cognitive impairment in PD23. The range of neurotransmitter changes demonstrate the com-
plex pathology of different cognitive impairments in PD.
Kehagia et al.4 suggest that genetic characteristics may account for patterns of decline in PD-MCI. The ‘dual 
syndrome hypothesis’ proposes two distinct genetic syndromes (executive and posterior cortical) that affect exec-
utive function and memory/visuospatial abilities in PD, and often present early in the disease4. A recent study 
tested this hypothesis and found associations between a genetic variation (rs4680 polymorphism of the COMT 
gene) which modulated executive function and two genetic variations (APOE allelic and MAPT haplotype) which 
independently modulated posterior cortical functions of memory and visuospatial abilities, respectively24. These 
studies provide initial evidence that frontal or posterior cortical cognitive deficits are associated with specific 
genetic and neurotransmitter abnormalities. Neuroimaging was beyond the scope of the present study, but the 
heterogeneity of multiple domain PD-MCI in this study does not support the ‘dual syndrome hypothesis’ (e.g., 
participants demonstrated many patterns of impairment across all cognitive domains). Having said this, research 
shows considerable overlap between the executive and posterior cortical syndromes and further clinical trials 
combining neuroimaging and neuropsychological testing are required25.
Participants with PD-MCI performed significantly worse (compared to participants with PD-NC) across all 
cognitive domains, including global cognition. Similar results were reported by Goldman et al.10 and Marras 
et al.11 In both of these studies, PD-MCI groups performed significantly worse on cognitive outcomes com-
pared to the unimpaired groups. Group allocation was determined by cognitive performance, and as such, sig-
nificant differences between group scores were to be expected. In this study, however, a conflicting result was 
reported for executive function. Compared to the Controlled Oral Word Association Test (COWAT), scores on 
the Stockings of Cambridge (SOC) test demonstrated no difference between groups, indicating comparative 
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performance between those with and without PD-MCI. A recent systematic review and meta-analysis highlighted 
the multifaceted nature of executive function and the challenges faced when researching this cognitive domain 
in PD26. Executive function is often referred to as an ‘umbrella’ concept used to describe many subcomponent 
abilities, including purposive action (execution), volition, planning, effective performance, attentional control, 
set-shifting, inhibition and managing behaviour27–29. Consequently, individual neuropsychological tests are often 
unable to capture and measure the full spectrum of executive function. Predominantly, the SOC test involves 
rule learning, planning and execution, whereas the COWAT requires set shifting (between trials) and attentional 
control. In addition, studies have shown separation of ‘hot’ and ‘cold’ executive function abilities. ‘Cold’ cognitive 
tasks are described as neutrally affective and involve cognitive flexibility, while ‘hot’ cognitive tasks are influenced 
by emotion and motivated reasoning30. Due to the complexity of executive function and the inherent specificity 
of neuropsychological tests, people with PD may show impaired performance on individual tests which do not 
represent impairment across the entire domain26. Therefore it is important that the exact tests used for diagnosis 
are standardised.
When examining demographic variables, there were no significant differences between groups. Participants 
in the PD-MCI group were slightly older and had slightly less years of education, but these differences were not 
significant. Recent studies have reported no educational difference between people with and without cognitive 
impairments in PD10–12,15. Some studies, however, reported older age and less years of education associated with 
cognitive decline in PD7,31,32. These conflicting results suggest future longitudinal research is required to deter-
mine the long-term relationship between years of education and cognitive impairment in PD. Due to participant 
burden, motor symptom severity was not directly measured in the current study. Levodopa equivalent dose and 
disease duration were measured and the findings indicate no group differences, which suggests severity of motor 
symptoms were similar across groups33.
Limitations and recommendations for future research. The main limitation of this study was the 
cross sectional design, which involved only baseline cognitive assessments. Collecting data at one time-point 
limits examination of which neuropsychological tests are most appropriate, and of which domains of impairment 
are most predictive of cognitive decline in PD. This sample had relatively high educational levels and low years of 
disease duration. These characteristics are comparable to cohorts from recent studies11,12, but may limit the gener-
alisability of the results to the wider PD population. Lastly, there was low internal consistency for some cognitive 
measures, which must be noted when interpreting the results.
Future studies should adopt longitudinal designs to validate and provide suggestions for the refinement of the 
MDS Task Force diagnostic criteria for PD-MCI. Future studies need to determine which neuropsychological 
tests are most reliable and valid over time, the most appropriate number of tests per cognitive domain (to control 
inflation of Type I errors), and the most sensitive and specific cut off scores for diagnostic purposes. The MDS 
criteria also needs to be applied to different age groups with varying degrees of cognitive impairment, disease 
severity and cognitive reserve (educational/occupational attainment). Recent and ongoing longitudinal studies 
are examining biomarker, epidemiological and neuropsychological risk factors associated with cognitive decline 
in PD7,20,24,32,34. However, future studies need to adopt an interdisciplinary approach by integrating clinical neuro-
science, neuroimaging and neurobiology with the MDS criteria, to provide a greater understanding of PD-MCI. 
Moreover, studies must be transparent in their reporting of the normative datasets used to establish diagnoses 
of PD-MCI. As explained by Strauss et al.35, selection of appropriate normative data is equally as important as 
choosing a reliable and valid neuropsychological test. Using a normative dataset that is not a demographical 
match to a participant’s characteristics is problematic, given that norm-referenced scores are directly related to 
clinical and research consequences such as prevalence rates, diagnosis, and pharmacological/nonpharmacolog-
ical interventions36.
The etiology and profile of PD-MCI is heterogeneous, with some people reverting back to normal cognition 
and many others progressing to PD-Dementia6. There is no current therapeutic intervention to halt or delay cog-
nitive decline in PD37. Clinical trials are examining the potential of pharmacological treatments, but two recent 
studies found no improvements in cognition38,39. The limited empirical support of pharmacological treatment for 
PD-MCI has led to an increase in research assessing nonpharmacological interventions for cognition in PD40. 
Specifically, cognitive training and non-invasive brain stimulation have improved cognition in PD41,42. However, 
most studies included participants without cognitive impairment and significant methodological heterogeneity 
limits the reliability of results37. Despite current limitations, nonpharmacological interventions may be a thera-
peutic alternative for people with PD-MCI who are already burdened by dopaminergic medications.
When applying the MDS Task Force diagnostic criteria for PD-MCI, this study found 64% of participants 
(using a 1 SD cut off) were cognitively impaired (i.e., demonstrated PD-MCI), and this figure reduced to 28% 
with PD-MCI when using a 2 SD cut off. Despite the change in frequency of impairments, most participants 
with PD-MCI were classified as multiple domain subtype which is consistent with recent findings21. Although 
further validation and refinement of the diagnostic criteria is required, the significant prevalence and heteroge-
neous nature of PD-MCI is well documented. Future studies need to integrate the MDS criteria with longitudinal 
designs of interdisciplinary research, to identify subtypes of PD-MCI and individuals most likely to develop 
PD-Dementia. Subtyping PD-MCI may also allow researchers to determine which subtypes will benefit from 
pharmacological and nonpharmacological interventions that may delay or halt progression of cognitive decline.
Method
This study used a cross-sectional design to measure cognition in people with PD, using the MDS diagnostic 
criteria for PD-MCI8. Neuropsychological assessments were completed at Curtin University’s Neuroscience 
Laboratory between March and September, 2015.
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Participants. Participants were adults with PD living in Western Australia. The following inclusion crite-
ria were used: (1) diagnosed with idiopathic PD by a neurologist or geriatrician in accordance with the United 
Kingdom Parkinson’s Disease Society Brain Bank Clinical Diagnostic Criteria, (2) a stable response to antipar-
kinsonian medication for a minimum period of 2 months, and (3) cognitive deficits that do not interfere with 
functional independence. Exclusion criterion was presence of PD-Dementia.
Neuropsychological assessment. Neuropsychological assessments were conducted in two phases. 
Participants were first screened over the telephone for the presence of dementia (using the TISC-30)43. 
Participants then completed an extensive neuropsychological assessment at Curtin University. In accordance 
with the MDS Task Force Level II diagnostic criteria for PD-MCI, two measures were selected to assess each of 
the five cognitive domains impacted in PD-MCI8. The following measures have been recommended by the MDS 
Task Force for use in PD and were used to assess functioning. Executive function was assessed using the Stockings 
of Cambridge (SOC) subtest from the Cambridge Neuropsychological Test of Automated Batteries (CANTABTM) 
and the phonemic verbal fluency subtest of the Controlled Oral Word Association Task (COWAT)44. Attention 
and working memory was assessed using the Letter-Number Sequencing (LNS) subtest from the Wechsler Adult 
Intelligence Scale-IV (WAIS-IV)45 and the Stroop (Colour-Word) Test46. Memory was assessed using the Hopkins 
Verbal Learning Test-Revised (HVLT-R)47 immediate recall subtest and the Paragraph Recall subtest of the 
Rivermead Behavioural Memory Test (RMBT)48. Visuospatial abilities were assessed using the Judgement of Line 
Orientation (JLO) test49 and the Hooper Visual Organisation Test (HVOT)50. Language was assessed using the 
Boston Naming Test-Short Form (BNT-Short Form)51 and the Similarities subtest from the WAIS-IV battery45.
Global cognition was assessed using the Parkinson’s Disease – Cognitive Rating Scale (PD-CRS)52 and the 
Mini Mental State Examination (MMSE)53. Premorbid intelligence and activities of daily living were assessed 
by the Australian version of the National Adult Reading Test (AUSNART)54 and Unified Parkinson’s Disease 
Rating Scale (section II)55, respectively. A UPDRS-II55 summary index score greater than 3 was used to exclude 
participants with impaired activities of daily living (i.e., cognitive deficits that significantly impact functional 
independence). Demographic information including age, disease duration (years) and current daily levodopa 
dopaminergic medication were also collected56. This study was approved by Curtin University’s Research Ethics 
Committee prior to contact with participants (approval number: HR 189/2014). All research methods were car-
ried out in accordance with ethics committee guidelines and all participants provided informed consent prior to 
completing neuropsychological assessments. All assessments were conducted during participants’ ‘ON’ stage of 
medication use.
Cognitive diagnosis. Following each assessment, results were scored and interpreted using standardised 
normative data from healthy older adults (Supplementary Table 1). PD-MCI was diagnosed as less than one stand-
ard deviation (SD) below normative scores on two or more neuropsychological tests8. The MDS Task Force suggest 
the use of 1 to 2 SD cut offs below normative scores. Raw scores were used to determine impairment on all tests, 
excluding the LNS and Similarities tests. The LNS and Similarities raw scores were converted into scaled scores 
(as per WAIS-IV instructions), and then compared to normative data45. In accordance with the MDS criteria8, 
a cut off of 1 SD was used in this study to accommodate the likelihood that the community based cohort may 
include higher functioning adults living independently, who may not report cognitive deficits but demonstrate 
impairment during formal neuropsychological assessment. Also, subjective report of cognitive decline has shown 
low accuracy in PD57. Therefore, individuals in this study were not required to meet the criteria of reporting 
cognitive decline. For participants who met the Level II criteria, the following PD-MCI subtype classifications 
were applied: (1) amnestic single domain (impairment on two memory tests); (2) nonamnestic single domain 
(impairment on two or more non-memory tests); (3) amnestic multiple domain (impairment on two or more 
tests, including memory) and (4) nonamnestic multiple domain (impairment on two or more tests, not including 
memory). Participants who did not meet the Level II criteria were classified as having ‘Normal Cognition’.
Statistical analysis. Statistical Package for the Social Sciences (SPSS) 22.0 was used for statistical analyses. 
Descriptive statistics for demographic data and neuropsychological test scores were computed, and frequency 
estimates were calculated to describe the prevalence of cognitive impairment and PD-MCI subtypes. Independent 
samples t tests and a Mann-Whitney U test (for a non-parametric outcome) were used to examine if there were 
statistically significant differences between the ‘PD-MCI’ and ‘Normal Cognition’ (i.e., those without PD-MCI) 
groups on demographic variables and neuropsychological outcomes58,59. An alpha level of 0.05 was applied to 
demographic variables and a Bonferroni-adjusted alpha level was applied to cognitive outcomes, where there 
were multiple comparisons per domain (i.e., p < 0.025). Where possible, the internal reliability of outcomes were 
computed using two methods: (1) the Kuder-Richardson 20 (KR-20), and (2) Cronbach’s α 60,61. Both methods 
produce estimates of internal consistency, though the KR-20 assesses tests with dichotomous response items (e.g., 
‘correct’ or ‘incorrect’) and Cronbach’s α examines tests with any response scale62. For cognitive tests, internal 
consistency of ≥ 0.70 is acceptable for research purposes59.
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